AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02838264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06463922
Description: Single oral dose of PF-06463922 50 mg on Day 1 of Period 1 and Day 5 of Period 2
Study NCT02838264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06463922
Description: Single oral dose of PF-06463922 75 mg on Day 1 of Period 1 and Day 5 of Period 2
Study NCT04904874 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: intense pulsed light
Description: treatment with 3 sessions of intense pulsed light, the second one after 2 weeks, the third one after 6 weeks
Study NCT00133601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: CBT-I including sleep restriction, stimulus control, sleep hygiene instructions and one session of cognitive therapy devoted to catastrophic thoughts about the consequences of insomnia.
Study NCT02632097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtenstein Hernioplasty with Sutures
Description: Procedure/Surgery: Lichtenstein Hernioplasty with Sutures: non-absorbable suture (polypropylene 2/0) is used for mesh fixation Other Name: prolene 2-0
Study NCT02838264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06463922
Description: Single oral dose of PF-06463922 100 mg on Day 1 of Period 1 and Day 5 of Period 2
Study NCT02838264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06463922
Description: Highest safe single oral dose (mg) of PF-06463922 identified in the previous cohorts will be administered on Day 1 of Period 1 and Day 5 of Period 2
Study NCT02838264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg oral dose of itraconazole on Days 1 to 11 during Period 2
Study NCT03618576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance specific exercise
Description: Balance specific exercise consists of total 10 days' physical therapy (PT) sessions (twice per day for 60 min) after surgery. It will be conducted with a computed posturographic system for diagnostics of balance and movement skills (Balance Master® System NeuroCom®) designed to objectively quantify balance and postural function of different origin. PT (weight-bearing, strengthening, gait training, aerobic, and functional exercises) was gradually increased based on the patient's functional level. Intensive patient education by multidisciplinary rehabilitation members was also provided.
Study NCT03796858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Description: Participants will receive guselkumab 100mg as SC injection.
Study NCT03796858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo as SC injection.
Study NCT03223025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CinnaTropin®
Description: 0.03 mg/kg daily subcutaneous injections
Study NCT03223025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CinnaTropin®
Description: 0.03 mg/kg daily subcutaneous injections
Study NCT03223025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nordilet®
Description: 0.03 mg/kg daily subcutaneous injections
Study NCT03223025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nordilet®
Description: 0.03 mg/kg daily subcutaneous injections
Study NCT03604016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifovir dipivoxil
Description: Besifovir dipivoxil 150 mg
Study NCT03604016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: Besifovir dipivoxil 150 mg
Study NCT03604016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Alafenamide
Description: Tenofovir Alafenamide 25mg
Study NCT01697631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals
Study NCT01697631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Administrated subcutaneously (s.c., under the skin) before lunch
Study NCT01267682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation
Description: Thirty minutes of cognitive stimulation delivered daily for thirty minutes.
Study NCT02213965 — intervention group
Intervention type: DEVICE
Intervention: Peripheral IV catheter
Description: Intravenous access according to Instructions For Use
Study NCT01820169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ;Accu-Chek Compact Plus LCM bulk Japan
Description: HbA1c would be changed by more careful control in blood glucose with SMBG.
Study NCT01348464 — intervention group
Intervention type: PROCEDURE
Intervention: single port appendectomy, three port appendectomy
Description: visual analog scale. questionnaire on wound satisfaction
Study NCT00703729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold Compression (CC)
Description: The device is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The device will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
Study NCT00703729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice Wrap (IW)
Description: The ice bag is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The ice bag is placed on the shoulder and the elastic wrap is used to hold the bag in place. The ice will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
Study NCT04123145 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iron status testing
Description: Iron status testing
Study NCT03193918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib
Description: Crenolanib continuously on Days 1-28 at 1 of 3 BID doses - 60 mg, 80 mg or 100 mg
Study NCT03193918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab IV 8 mg/kg on Days 1 and 15 q28 days
Study NCT03193918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV 80 mg/m2 on Days 1, 8 and 15 q28 days
Study NCT00757055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine titrated to heart rate starting at 5 mg bd and increasing to maximum of 7.5 mg bd or reducing to 2.5 mg if heart rate \< 60 bpm.
Study NCT00757055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active treatment given
Study NCT00782054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Provase
Description: NDC:60230-8573-0 Over the counter (OTC) moisturizer containing 2% dimethicone and a blend of endopeptidases. Use topically to affected area every 8 hours.
Study NCT00782054 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control moisturizer
Description: Over the counter (OTC) moisturizer containing 2% dimethicone. Use topically to affected area every 8 hours. Does NOT contain endopeptidases. Placebo intervention is identical to active intervention EXCEPT it does not contain endopeptidases.
Study NCT02386137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhancement ultrasound with Sonovue
Study NCT03895814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protective Step Training
Description: Participants will undergo 6, 1 hour visits (over the course of 2 weeks) where they will be exposed to repeated slips on a treadmill.
Study NCT04513392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: A flexible laser fiber will be utilized via a channelled laryngoscope to ablate the benign laryngeal lesions as per standard of care.
Study NCT04513392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser treatment
Description: A flexible laser fiber will be utilized via a channelled laryngoscope to ablate the benign laryngeal lesions as per standard of care.
Study NCT03744247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Study NCT03744247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Study NCT03744247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: 3mg/kg intravenously every 2 weeks
Study NCT03744247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intravenously every 2 weeks
Study NCT03995277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Biotin
Description: Daily intake of 10 mg or 50 µg per day
Study NCT00264576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine
Study NCT04531007 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iFR/ FFR/ IVUS/ OCT
Description: intermediate lesion evaluation with intracoronary physiology and imaging
Study NCT02980432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: changes in whole-body roll position and visual/haptic stimuli presented
Description: In different whole-body roll positions subjects will be presented a luminous line or a rod in combination with a moving or stationary background. Participants will be asked to align the line or the rod along perceived direction of gravity.
Study NCT02470312 — intervention group
Intervention type: PROCEDURE
Intervention: CRT implantation
Description: It is a novel 3D electromagnetic navigation system (MediGuide™) that is capable of non-fluoroscopic navigation of sensor-enabled tools in the x-ray environment
Study NCT02470312 — intervention group
Intervention type: DEVICE
Intervention: MediGuide
Study NCT03817645 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Zeolite
Description: The natural zeolite clinoptilolite is of volcanic origin. The mineral belongs to the group of zeolite minerals. Zeolites are silicates with a microporous structure. This results in a stable structure with nanometer-sized cavities that pass through the natural zeolite clinoptilolite - comparable to a mineral sponge. Due to the numerous pores and channels, the mineral has a large internal surface and it can absorb molecules that are smaller in diameter than the pore openings. Since zeolite clinoptilolite has an anionic charge, there are cations such as Na +, K +, Ca 2+, Mg 2+ which can be exchanged for other ions (e.g., Pb\^2+) in the cavities for electrical charge balance. In particular, the ion exchange capacity is essential for the effect and is used in many areas.
Study NCT03932396 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: No intervention is planned outside of usual clinical practice. Only active screening for hepatotropic virus infection, mainly hepatitis C virus, HIV, and mental illness will be carried out. If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.
Study NCT02470312 — intervention group
Intervention type: PROCEDURE
Intervention: EP
Study NCT00700557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics - Lactobacillus casei and Bifidobacterium breve
Description: Experimental group:This group received enteral tube feeding or oral diet plus a juice containing 1 sachet (1g) of probiotics (Lactobacillus casei and Bifidobacterium breve - 6x 108 UFC/g) three times a day.
Study NCT00700557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maize starch
Description: Placebo group: This groups received enteral tube feeding or oral diet plus a juice containing,approximately, 725mg of placebo three times a day.
Study NCT00753337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assurant® Cobalt Iliac Stent System
Description: Iliac Stenting
Study NCT03733574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005
Description: Drug: LY03005 80 mg, oral tablets, single dose
Study NCT03817645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zeolite
Description: The natural zeolite clinoptilolite is of volcanic origin. The mineral belongs to the group of zeolite minerals. Zeolites are silicates with a microporous structure. This results in a stable structure with nanometer-sized cavities that pass through the natural zeolite clinoptilolite - comparable to a mineral sponge. Due to the numerous pores and channels, the mineral has a large internal surface and it can absorb molecules that are smaller in diameter than the pore openings. Since zeolite clinoptilolite has an anionic charge, there are cations such as Na +, K +, Ca 2+, Mg 2+ which can be exchanged for other ions (e.g., Pb\^2+) in the cavities for electrical charge balance. In particular, the ion exchange capacity is essential for the effect and is used in many areas.
Study NCT01259479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satraplatin
Description: Orally, once daily for 5 days repeated every 28 days, dose-escalation
Study NCT04499469 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spreader Graft
Description: To place and attach with 5.0 PDS suture 2 grafts in the middle third of the nose
Study NCT03733574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pristiq
Description: Drug: Pristiq 50 mg, oral tablets, single dose
Study NCT03309501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tong-Luo-Qu-Tong Plaster
Description: for 14 days as two period of treatment, daily 1 time.
Study NCT03309501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qi-Zheng-Xiao-Tong Plaster
Description: for 14 days as two period of treatment, daily 1 time
Study NCT01044550 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopy
Description: Treatment group will undergo a laparoscopy, with repair of the diaphragm if injury found
Study NCT01044550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical follow up
Description: Control group will undergo no treatment except suturing of wounds and drainage of the hemo-pneumothorax, if present. Then clinical follow up.
Study NCT01494116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 900 mL of 0.9% Normal Saline
Description: The intervention consists of the administration of 900 mL of Normal Saline to the model using the Disconnection- Reconnection method of manual fluid resuscitation. All syringes (syringe size based on study arm) will be prepared by research staff following subject randomization. Each subject will take the prepared syringes, and sequentially administer them to the model by 1. Selecting and connecting a fluid-filled syringe to the catheter extension set to permit fluid administration 2. Manually administering the fluid to the model by depressing the syringe plunger 3. Disconnecting and discarding the empty syringe 4. Repeating steps 1-3 as fast as possible until all 900 mL has been administered.
Study NCT01380743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duvoglustat
Description: Single oral dose
Study NCT01380743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGAA
Description: Single intravenous infusion
Study NCT05706688 — intervention group
Intervention type: PROCEDURE
Intervention: Anesthetic technique (regional versus general)
Description: Anesthetic technique (regional versus general)
Study NCT02626143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational nutrient-rich whey protein formula
Study NCT02626143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk based formula
Study NCT00461695 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vaccination against TBEV (FSME Immun CC)
Description: Intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
Study NCT04213456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Sport Formula
Description: Powder added to water,high protein and multi vitamins and minerals
Study NCT04213456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Low caloric formula (Powder added to water), without added vitamins and minerals.
Study NCT03681457 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LJN452
Description: Dose A single dose
Study NCT03681457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJN452
Description: Dose A single dose
Study NCT00579826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.
Study NCT00579826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet daily for 6 months then optional open label letrozole for 6 months.
Study NCT02048553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet-guided ventriculostomy
Description: In patients of the treatment group, ventriculostomy will be performed using a mini-tablet-guided assistance based on preoperative CT imaging. Any patient meeting the inclusion criteria and not violating the exclusion criteria may participate in the TABGUIDE study and be randomized to either a guided or freehand ventriculostomy, thus defining the two distinct groups  guided  or  freehand ).
Study NCT02048553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freehand
Description: Patients in the control group will receive standard free-hand ventriculostomy using anatomical landmarks. The catheter may be placed for external drainage or internal (ventriculoperitoneal) shunting in both groups.
Study NCT04894136 — intervention group
Intervention type: PROCEDURE
Intervention: ICSI-TESE; embryo-transfer
Description: The sperm injected into the cytoplasm of an oocyte (Intracytoplasmatic Sperm Injection) is obtained by testicular extraction. Ultrasound guided transvaginal embryo transfer.
Study NCT03938857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl standard of care
Study NCT03938857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl standard of care
Study NCT03938857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine (0.5 mcg/kg + 0.2 mcg/kg/hr)
Study NCT05746156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lymphatic mapping
Description: 1. Peritumoral injection of \[99mTc\]Tc-nanocolloid in 6-8 evenly distributed depots on both sides of the tumor, during investigation under anaesthesia. Number of depots depending on the size and localisation of the tumor.~2. Planair and SPECT/CT imaging van de abdomen/pelvis 3h and 12-24h after injection at the department of radiology and nucleair medicine.
Study NCT03938857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine (0.5 mcg/kg + 0.5 mcg/kg/hr)
Study NCT03938857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine (0.5 mcg/kg + 0.7 mcg/kg/hr)
Study NCT01454895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sampler of hearing protection devices
Description: In a pilot study, hearing protection devices were mailed to farmers, resulting in a significant increase in use. These results suggested that overall, HPDs were acceptable to farmers, and that access to HPDs may be an important contributor to frequency of use. The study will build on this earlier work by providing an assortment of hearing protection devices to a sub-sample of each group of farmers receiving the Interactive and Static Web Interventions. The assortment includes the most commonly used types of devices (i.e., muffs, foam plugs, pre-molded plugs, and semi-aurals). The sampler is delivered, together with manufacturers' standard written instructions for use, via mail at the designated time according study design.
Study NCT01454895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Static Web-based information
Description: The standard information promoting HPD use delivered via Internet will be based on an informational brochure previously developed for use by farmers (i.e., Have You Heard? and They're Your Ears Protect Them). These brochures, including color graphics and text, are available on the Internet (as PDF files). Although they have been printed and distributed by NIOSH, most farmers will not have been exposed to copies. There are important differences between the SWI and IWI interventions, including interactivity, animation, explication of farmer-generated tips and techniques for addressing common barriers to hearing protector use, use of color, audio, and video, hotlinks, and farmer testimonials.
Study NCT01454895 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Static Web-based information
Description: The standard information promoting HPD use delivered via Internet will be based on an informational brochure previously developed for use by farmers (i.e., Have You Heard? and They're Your Ears Protect Them). These brochures, including color graphics and text, are available on the Internet (as PDF files). Although they have been printed and distributed by NIOSH, most farmers will not have been exposed to copies. There are important differences between the SWI and IWI interventions, including interactivity, animation, explication of farmer-generated tips and techniques for addressing common barriers to hearing protector use, use of color, audio, and video, hotlinks, and farmer testimonials.